ImmunityBio Statistics Share Statistics ImmunityBio has 945.25M
shares outstanding. The number of shares has increased by 26.72%
in one year.
Shares Outstanding 945.25M Shares Change (YoY) 26.72% Shares Change (QoQ) 3.42% Owned by Institutions (%) 9.53% Shares Floating 98.33M Failed to Deliver (FTD) Shares 16,221 FTD / Avg. Volume 0.19%
Short Selling Information The latest short interest is 76.98M, so 8.72% of the outstanding
shares have been sold short.
Short Interest 76.98M Short % of Shares Out 8.72% Short % of Float 33.7% Short Ratio (days to cover) 12.54
Valuation Ratios The PE ratio is -4.32 and the forward
PE ratio is -7.18.
ImmunityBio's PEG ratio is
0.09.
PE Ratio -4.32 Forward PE -7.18 PS Ratio 121.07 Forward PS 9.7 PB Ratio -3.66 P/FCF Ratio -4.48 PEG Ratio 0.09
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for ImmunityBio.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.36,
with a Debt / Equity ratio of -1.03.
Current Ratio 3.36 Quick Ratio 3.21 Debt / Equity -1.03 Debt / EBITDA -2.09 Debt / FCF -1.27 Interest Coverage -2.23
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $21.97K Profits Per Employee $-616.34K Employee Count 671 Asset Turnover 0.04 Inventory Turnover n/a
Taxes Income Tax 81K Effective Tax Rate -0.02%
Stock Price Statistics The stock price has increased by -44.34% in the
last 52 weeks. The beta is -0.07, so ImmunityBio's
price volatility has been lower than the market average.
Beta -0.07 52-Week Price Change -44.34% 50-Day Moving Average 2.77 200-Day Moving Average 3.2 Relative Strength Index (RSI) 40.41 Average Volume (20 Days) 8,680,761
Income Statement In the last 12 months, ImmunityBio had revenue of 14.74M
and earned -413.56M
in profits. Earnings per share was -0.59.
Revenue 14.74M Gross Profit 14.74M Operating Income -344.18M Net Income -413.56M EBITDA -241.76M EBIT -259.32M Earnings Per Share (EPS) -0.59
Full Income Statement Balance Sheet The company has 143.43M in cash and 504.17M in
debt, giving a net cash position of -360.74M.
Cash & Cash Equivalents 143.43M Total Debt 504.17M Net Cash -360.74M Retained Earnings -3.38B Total Assets 402.08M Working Capital 157.49M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -391.24M
and capital expenditures -6.89M, giving a free cash flow of -398.12M.
Operating Cash Flow -391.24M Capital Expenditures -6.89M Free Cash Flow -398.12M FCF Per Share -0.57
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -2334.23% and -2804.77%.
Gross Margin 100% Operating Margin -2334.23% Pretax Margin -2804.77% Profit Margin -2804.77% EBITDA Margin -1639.63% EBIT Margin -2334.23% FCF Margin -2700.06%
